Person:
SARIYAR AKBULUT, BERNA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

SARIYAR AKBULUT

First Name

BERNA

Name

Filters

2022 - 20233
Reset filters

Settings

Subject: Clinical Medicine (MED) ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Screening of FDA-Approved Natural Drugs as Anti-Virulence Agents Against Pseudomonas aeruginosa and Neisseria meningitides.
    (2022-06-30) KULA, CEYDA; ÖZBEK SARICA, PEMRA; SARIYAR AKBULUT, BERNA; Özcan A., Kula C., Avcı F. G., Keskin Özkaya Z. Ö., Özbek Sarıca P., Sarıyar Akbulut B.
  • Thumbnail Image
    PublicationOpen Access
    A review on the mechanistic details of OXA enzymes of ESKAPE pathogens
    (2023-01-01) SARIYAR AKBULUT, BERNA; ÖZBEK SARICA, PEMRA; Avci F. G., Tastekil I., Jaisi A., ÖZBEK SARICA P., SARIYAR AKBULUT B.
    The production of beta-lactamases is a prevalent mechanism that poses serious pressure on the control of bacterial resistance. Furthermore, the unavoidable and alarming increase in the transmission of bacteria producing extended-spectrum beta-lactamases complicates treatment alternatives with existing drugs and/or approaches. Class D beta-lactamases, designated as OXA enzymes, are characterized by their activity specifically towards oxacillins. They are widely distributed among the ESKAPE bugs that are associated with antibiotic resistance and life-threatening hospital infections. The inadequacy of current beta-lactamase inhibitors for conventional treatments of \"OXA\" mediated infections confirms the necessity of new approaches. Here, the focus is on the mechanistic details of OXA-10, OXA-23, and OXA-48, commonly found in highly virulent and antibiotic-resistant pathogens Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Enterobacter spp. to describe their similarities and differences. Furthermore, this review contains a specific emphasis on structural and computational perspectives, which will be valuable to guide efforts in the design/discovery of a common single-molecule drug against ESKAPE pathogens.
  • No Thumbnail Available
    PublicationMetadata only
    Investigation of the Inhibition of Pseudomonas aeruginosa Type IV Pili Elongation ATPases to Prevent Biofilm Formation.
    (2022-11-04) KULA, CEYDA; ÖZBEK SARICA, PEMRA; SARIYAR AKBULUT, BERNA; Kula C., Avcı F. G., Keskin Özkaya Z. Ö., Özbek Sarıca P., Sarıyar Akbulut B.